ストックスクリーナーアプリを入手
6.85
0.74%
0.05
プレマーケット:
5.73
-1.12
-16.35%
前日終値:
$6.80
開ける：
$6.69
24時間の取引高:
654.93K
Relative Volume:
1.10
時価総額：
$264.32M
収益：
-
当期純損益:
$-42.05M
株価収益率:
-2.4291
EPS:
-2.82
ネットキャッシュフロー:
$-35.26M
1週間 パフォーマンス:
-7.49%
1か月 パフォーマンス:
+47.47%
6か月 パフォーマンス:
+112.73%
1年 パフォーマンス:
+93.50%
1日の値動き範囲:
$6.65
$7.05
1週間の範囲:
$6.21
$7.54
52週間の値動き範囲:
$2.77
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
名前
Protara Therapeutics Inc
セクター
電話
646-844-0337
住所
345 PARK AVENUE SOUTH, NEW YORK, NY
TARA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
6.85 | 262.39M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-16 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 再開されました | Guggenheim | Buy |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-17 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Cowen | Outperform |
| 2020-07-29 | 開始されました | Guggenheim | Buy |
すべてを表示
Protara Therapeutics Inc (TARA) 最新ニュース
Protara Therapeutics Prices $75 Million Share Offering - marketscreener.com
Protara Therapeutics (TARA) Launches $75M Public Offering - GuruFocus
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
TARA Stock Offering Priced at Lower End of Target Range - GuruFocus
Will Protara Therapeutics Inc. (1KPA) stock benefit from sector leadership2025 Retail Activity & Safe Entry Point Alerts - Newser
Protara Therapeutics prices $75 million public offering - Investing.com
Protara Therapeutics prices $75 million public offering By Investing.com - Investing.com UK
Protara prices public offering of 13.04 million shares at $5.75 each - marketscreener.com
Protara Therapeutics (Nasdaq: TARA) prices 13,043,479-share, $75M public deal - Stock Titan
Protara Announces Pricing of $75 Million Public Offering - GlobeNewswire
Key Managers Announced for TARA Offering - GuruFocus
Protara Therapeutics Launches Offering of Securities - marketscreener.com
Protara Therapeutics stock tumbles after $75M public offering - Investing.com
Protara Therapeutics announces $75 million public offering By Investing.com - Investing.com South Africa
Protara Therapeutics Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Protara Announces Proposed Public Offering - GlobeNewswire
Protara Therapeutics (Nasdaq: TARA) starts $75M stock and pre-funded warrant sale - Stock Titan
Protara Therapeutics (NASDAQ:TARA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients - MarketScreener
Protara Therapeutics: End Of 2025 Proving Eventful Indeed (NASDAQ:TARA) - Seeking Alpha
Why Protara Therapeutics Inc. (1KPA) stock is listed among top recommendationsEarnings Overview Report & Daily Stock Trend Reports - Newser
Protara Therapeutics (NASDAQ:TARA) Receives Buy Rating from HC Wainwright - Defense World
Protara announces proposed public offering - MSN
HC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy Recommendation - Nasdaq
TARA: HC Wainwright & Co. Reiterates 'Buy' Rating with $23 Targe - GuruFocus
TARA: TARA-002 shows 69% six-month CR and strong safety in BCG naive NMIBC, advancing to registrational trial - TradingView
Protara Reports Updated Interim Phase 2 Data Of TARA-002 In Non-muscle Invasive Bladder Cancer - RTTNews
Protara Therapeutics reports positive results from bladder cancer study - Seeking Alpha
Protara Therapeutics, Inc. (TARA) Jumps 14.6% in Pre-market Trading: After Positive Data Release - Stocks Telegraph
Protara Therapeutics (TARA) Reveals Promising Data from Phase 2 Bladder Cancer Trial - GuruFocus
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - marketscreener.com
Is Protara Therapeutics Inc. (1KPA) stock attractive for dividend growthTrade Entry Summary & Safe Capital Allocation Plans - Newser
Adversity is less terrifying than hope: Protara Therapeutics Inc (TARA) - Setenews
Will Protara Therapeutics Inc. (1KPA) stock sustain uptrend momentum2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Protara to host conference call on TARA-002 bladder cancer trial data - Investing.com Nigeria
Protara Therapeutics to Host Conference Call on December 3 to Discuss Interim Phase 2 Data for TARA-002 in Bladder Cancer - Quiver Quantitative
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Is Protara Therapeutics Inc. stock trading near support levelsJuly 2025 Sentiment & Stock Portfolio Risk Control - BỘ NỘI VỤ
Why Protara Therapeutics Inc. stock could outperform in 2025Earnings Miss & Short-Term Swing Trade Alerts - BỘ NỘI VỤ
This Insider Bought 20000.0 Shares In Protara Therapeutics Inc (TARA) - fostersleader.com
HC Wainwright Has Positive Outlook for TARA Q4 Earnings - MarketBeat
HC Wainwright Has Positive Forecast for TARA Q4 Earnings - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Brokers Set Expectations for TARA Q2 Earnings - Defense World
Protara sees Chugai blue sky in LMs as phase II data strong - BioWorld MedTech
What analysts say about Protara Therapeutics Inc stockBullish Engulfing Patterns & Low Risk Trading Portfolio - earlytimes.in
Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30% - Yahoo Finance
Revenue per share of Protara Therapeutics, Inc. – HAM:1KPA - TradingView
Will Protara Therapeutics Inc. (1KPA) stock maintain strong growthWeekly Volume Report & Target Return Focused Picks - newser.com
Protara Therapeutics Inc (TARA) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):